{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cervical-cancer-hpv/diagnosis/clinical-features/","result":{"pageContext":{"chapter":{"id":"0a170049-907b-518b-9506-127d186d0a96","slug":"clinical-features","fullItemName":"Clinical features","depth":2,"htmlHeader":"<!-- begin field b9bad1d9-eb57-4439-827d-824373aad947 --><h2>What clinical features could indicate cervical cancer?</h2><!-- end field b9bad1d9-eb57-4439-827d-824373aad947 -->","summary":"","htmlStringContent":"<!-- begin item 61decbc3-53b4-4515-bd11-f4743dd789a8 --><!-- begin field c9ce9e73-cb59-4c24-be38-81509255472c --><p>Many women with cervical cancer will be asymptomatic and are diagnosed through the NHS Cervical Screening Programme because of a positive HPV test, abnormal cervical cytology, and subsequent colposcopy and biopsy. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cervical-screening/\">Cervical screening</a>.</p><ul><li>Consider the possibility of cervical cancer in a woman who has any of the following nonspecific symptoms:<ul><li>Intermenstrual bleeding.</li><li>Postcoital bleeding (risk of cervical cancer increases with age).</li><li>Postmenopausal bleeding.</li><li>Blood-stained vaginal discharge.</li><li>Mucoid, or purulent vaginal discharge.</li><li>Pelvic pain/dyspareunia.</li></ul></li><li>Rarely, women may present with advanced cancer with such symptoms as pelvic discomfort or pain, renal failure, leakage of urine or faeces from a fistula, lymphoedema, or severe haemorrhage.</li><li>On examination:<ul><li>The cervix may appear inflamed or friable and bleed on contact (although the most likely cause for this will be <em>Chlamydia trachomatis.</em> For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/diagnosis/differential-diagnosis/\">Differential diagnosis</a>).</li><li>There may be a visible ulcerating or fungating lesion or a foul-smelling serosanguineous vaginal discharge.</li></ul></li></ul><!-- end field c9ce9e73-cb59-4c24-be38-81509255472c --><!-- end item 61decbc3-53b4-4515-bd11-f4743dd789a8 -->","topic":{"id":"38328a3b-8997-55f8-afac-19e980523812","topicId":"e2dafa6e-4749-48b2-b981-fa906c90d627","topicName":"Cervical cancer and HPV","slug":"cervical-cancer-hpv","lastRevised":"Last revised in September 2020","chapters":[{"id":"417b3c03-a940-5eb6-8b35-698036862be5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b4186a4a-8c1e-51ad-9743-d00be5b18f3d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c2a58da0-8965-5522-8b3d-618890f730d3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2a436c60-1809-5f9f-bf39-409fd07e7af5","slug":"changes","fullItemName":"Changes"},{"id":"6b2a8979-8ca9-5087-a80b-ea14445c034a","slug":"update","fullItemName":"Update"}]},{"id":"c207e9ef-e492-5e67-8986-8b48ff76c55f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4e791e8f-015d-58bd-99ec-2689c4baa3e4","slug":"goals","fullItemName":"Goals"},{"id":"b04fb3a0-7363-5d87-b475-a7ad1e7ca9af","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"af911672-6dba-57d0-b3bf-4058c30f91ff","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"16911bc4-aa1d-56b2-aaf3-39695a5692f3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9c781faa-cf3f-5dcc-b39d-4c10588cbbfb","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"713db7a4-b4c8-55f3-8ca0-e5c0db230466","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2f3819e7-a39a-5399-98a2-014b4d9243c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e32e97af-cb99-5487-8ceb-1d8db9b2fe5f","slug":"types-of-cervical-cancer","fullItemName":"Types of cervical cancer"},{"id":"02013d86-5f8b-50e2-8bbc-9e9e5335f72d","slug":"causes","fullItemName":"Causes"},{"id":"961e80d0-b721-5756-b1df-56633ce9e5aa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4a62390f-59b9-5d3c-ad78-0394d8900138","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5f216154-2a06-5aee-9270-f2388b590979","slug":"prognosis","fullItemName":"Prognosis"},{"id":"98782e4e-b481-5526-803b-b5f18e566c5d","slug":"complications","fullItemName":"Complications"}]},{"id":"0158af19-7ed5-56ac-a299-796dcf69f9a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0a170049-907b-518b-9506-127d186d0a96","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"ae89986b-d468-50ca-b0d4-788dce1cc020","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5aee8849-a5fc-592a-ba2f-161843f6a42e","slug":"cervical-cytology-sample","fullItemName":"Cervical cytology sample"},{"id":"8b13c601-cb6f-536e-a6cc-90001fa3357a","slug":"hpv-screening","fullItemName":"HPV screening"},{"id":"a05197b4-af3e-5fcb-9458-ec6446bb0cb9","slug":"referral","fullItemName":"Referral"}]},{"id":"75bee623-8a4b-5b31-b85b-b1f0cf45212d","fullItemName":"Management","slug":"management","subChapters":[{"id":"3918bf03-5c07-5c8f-bb28-5834e5dc1343","slug":"prevention","fullItemName":"Scenario: Prevention"},{"id":"5d0f88a0-5a31-5e1f-81ee-89cc202d9885","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"64ce0536-0d7d-554e-afc1-7859f158b82c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f4263e46-d3a8-5853-904f-7c0e9b926a1c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b9af798-d073-5ea1-a174-157b46c68062","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e827e587-3f77-5c14-92f8-58f34c105bbe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"22b0924c-0e7d-5a46-b369-dd38ebbc4a39","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f012ac60-98ba-56b3-838a-7924e3544719","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"102ef6c4-0635-5f17-a33b-e2d83ec751b0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1f31eeae-6068-5e2c-8097-3666754f067e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0158af19-7ed5-56ac-a299-796dcf69f9a8","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"5064753e-0894-5ae3-819a-77144ea7e477","slug":"basis-for-recommendation-213","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 3bc87912-2320-4df4-bde0-50525361b7aa --><h3>Basis for recommendation</h3><!-- end field 3bc87912-2320-4df4-bde0-50525361b7aa -->","summary":null,"htmlStringContent":"<!-- begin item 21396d27-8079-4c80-bfac-bddcd42b819d --><!-- begin field e1fb85bf-b373-4732-bf65-c388046d38ea --><p>This information is based on the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of cervical cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">SIGN, 2008</a>], the British Medical Journal (BMJ) best practice guideline <em>Cervical cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">BMJ, 2016</a>], expert opinion in narrative reviews <em>Management of cervical cancer </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Blomfield, 2007</a>], <em>Diagnosis and management of cervical cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Petignat and Roy, 2007</a>], and a systematic review on postcoital bleeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Shapley, 2006</a>].</p><h4>Nonspecific symptoms</h4><ul><li>16–32% of women with early-stage cervical cancer have symptoms at presentation, however, symptoms of cervical cancer are non-specific [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">SIGN, 2008</a>].</li></ul><h4>Post-coital bleeding</h4><ul><li>The prevalence of post-coital bleeding in the community is 0.7–9%, while in women with cervical cancer, it varies between 0.7% and 39% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Shapley, 2006</a>]<ul><li>It is not known how many women with post-coital bleeding in the community who present to primary care are referred to secondary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Shapley, 2006</a>].</li></ul></li><li>On average, only 2% of women seen in secondary care with post-coital bleeding have cervical cancer. The likelihood that a woman in the community with post-coital bleeding has cervical cancer is [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">SIGN, 2008</a>]:<ul><li>1 in 44,000 if 20–24 years of age.</li><li>1 in 56,000 if 25–34 years of age.</li><li>1 in 2800 if 35–44 years of age.</li><li>1 in 2400 if 45–54 years of age.</li></ul></li></ul><!-- end field e1fb85bf-b373-4732-bf65-c388046d38ea --><!-- end item 21396d27-8079-4c80-bfac-bddcd42b819d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}